Variations in circulating cytokine levels during 52 week course of treatment with SSRI for major depressive disorder

Hernández, Marı́a Eugenia; Mendieta, Danelia; Martínez‐Fong, Daniel; Loría, Frida; Moreno, Julia; Estrada, Iris; Bojalil, Rafael; Pavón, Lenin

doi:10.1016/j.euroneuro.2008.08.001

Cited by 125 publications

(84 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The intention of our analysis was exploratory, and in paper IV our results were compared with other studies using multiplex analyses. The lack of association between cytokines and depression observed in our study is in contrast to three other studies that showed increased concentrations of one or more of the pro-inflammatory cytokines IL-1 , IL-2, IL-6, IL-7, IL-8, IL-12(p70), MIP-1 and MCP-1 (133)(134)(135)(136). Consistent with our results, the study by Lehto et al showed no or weak associations (137;138).…”

Section: Major Depressive Disorder Novel Inflammatory Biomarkers Andcontrasting

confidence: 55%

Prevalence of cardiovascular risk factors and concentration of C-reactive protein in Type D personality persons without cardiovascular disease

Einvik

Dammen

Hrubos‐Strøm

et al. 2011

European Journal of Cardiovascular Prevention & Rehabilitat

View full text Add to dashboard Cite

Background: Type D personality is associated with poor cardiovascular outcome in patients with coronary or peripheral arterial disease. Whether Type D personality is associated with cardiovascular risk in persons without overt cardiovascular disease remains unknown. We hypothesized that Type D personality is associated with higher prevalence of traditional cardiovascular risk factors and higher concentration of C-reactive protein. Design: Cross-sectional study. Methods: Type D personality was assessed in 453 participants without cardiovascular disease derived from an epidemiological study of obstructive sleep apnoea. An evaluation of obesity, lipid status, diabetes, blood pressure, heart rate, smoking, leisure-time physical activity and high-sensitivity C-reactive protein was performed. Results: Smoking (43% vs. 21%, P < 0.001) and low leisure-time physical activity (<3 hours/week, 57% vs. 40%, P = 0.003) were more prevalent, and heart rate (mean (standard deviation), 75 (10) vs. 71 (9), P = 0.001) and body mass index was higher (29.8 (6.0) vs. 28.4 (4.5) kg/m2, P = 0.009) in Type D compared to non-Type D participants. The total number of risk factors was significantly higher in Type D than non-Type D participants (3.4 (1.3) vs. 3.0 (1.2), P = 0.004). The concentration of C-reactive protein was higher in participants with Type D personality (median, interquartile range 1.6, 0.7–3.4 vs. 1.1, 0.6–2.6, P = 0.047), although not statistically significant after adjustment for possible mediating factors. Conclusions: Among participants at high risk of cardiovascular disease, presence of Type D personality was associated with elevated body mass index and unhealthy behaviour such as smoking and low physical activity, which may have mediated the elevated concentration of C-reactive protein.

show abstract

Section: Major Depressive Disorder Novel Inflammatory Biomarkers Andcontrasting

confidence: 55%

Prevalence of cardiovascular risk factors and concentration of C-reactive protein in Type D personality persons without cardiovascular disease

Einvik

Dammen

Hrubos‐Strøm

et al. 2011

European Journal of Cardiovascular Prevention & Rehabilitat

View full text Add to dashboard Cite

show abstract

“…For some assays, the proteins could not be detected in more than 60% of the tested sera (Table 2). Indeed, both platforms failed to robustly detect the GM-CSF, IL-1β, IL-2 and IL-5 cytokines for which previous investigations had reported significant variations in expression either during MDE treatment or at baseline in comparison to healthy controls (Biancotto et al, 2013;Dahl et al, 2014;Hernandez et al, 2008;Schmidt et al, 2014;Shelton et al, 2015). These types of inconsistency in the results have already been reported (Breen et al, 2011;Chaturvedi et al, 2011;Dabitao et al, 2011;Dupuy et al, 2013;Fu et al, 2010).…”

Section: Discussioncontrasting

confidence: 44%

How to: Measuring blood cytokines in biological psychiatry using commercially available multiplex immunoassays

Belzeaux

Lefebvre

Lazzari

et al. 2017

Psychoneuroendocrinology

View full text Add to dashboard Cite

Cytokines produced by both immune and non-immune cells are likely to play roles in the development and/or progression of psychiatric disorders. Indeed, many investigators have compared the blood cytokine levels in psychiatric patients with those of healthy controls or monitored their levels in patients during disease progression to identify biomarkers. Nevertheless, very few studies have confirmed that such cytokines remain stable in healthy individuals through periods of weeks and months. This is an important issue to consider before using blood cytokine levels as biomarkers of disease traits, disease state, or treatment response. Although multiplex assay technology represents an advance in identifying biomarkers because it allows simultaneous examination of large panels of analytes from a small volume of sample, it is necessary to verify whether these assays yield enough sensitivity and reproducibility when applied to the blood from neuropsychiatric patients. Therefore, we compared two multiplex immunoassays, the bead-based Luminex® (Bio-Rad) and the electro-chemiluminescence-based V-plex® (MesoScaleDiscovery), for the detection and quantification of 31 cytokines, chemokines and growth factors in both the sera and plasma of patients with major depressive episodes (MDE) and age-and sex-matched healthy control subjects during a 30-week period. Although both platforms exhibited low coefficients of variability (CV) between the duplicates in the calibration curves, the linearity was better in general for the V-PLEX® platform. However, neither platform was able to detect the absolute values for all of the tested analytes. Among the 16 analytes that were detected by both assays, the intra-assay reproducibility was in general better with the V-PLEX® platform. Although it is not a general rule that the results from sera and plasma will be correlated, consistent results were more frequent with the V-PLEX® platform. Furthermore, the V-PLEX® results were more consistent with the gold standard ELISA simplex assay for IL-6 in both sera and plasma. The intra-individual variability of the measurements, among the sera and plasma for the 4 samples harvested from each healthy individual, was low for Eotaxin, G-CSF, IL-4, IL-7, IL-9, IL-12p40, IL-12p70, IL-15, MIP-1β, PDGF-BB, TNF, TNF-β and VEGF, but intermediate or high for IFN-γ, IL-6, IL-8, IL-10, and IP10. Together, these data suggest that extreme caution is needed in translating the results of multiplex cytokine profiling into biomarker discovery in psychiatry. Dear Editor,We thank you and the Editor in chief, Robert Dantzer, for reaching the conclusion to ultimately publish our manuscript. Following your suggestion, we changed the tiltle to: "How to: Measuring blood cytokines in biological psychiatry using commercially available multiplex immunoassays".We were concerned by the persistent negative comments of Reviewer#3, stressing out that our comparison between the two platforms we have worked with suffers a number of theoretical and technical limitations because...

show abstract

“…Twenty-two studies, comprising 603 subjects, fulfilled the inclusion criteria (Maes et al, 1995(Maes et al, , 1997Sluzewska et al, 1995;Frommberger et al, 1997;Hinze-Selch et al, 2000;Kubera et al, 2000;Kagaya et al, 2001;Mikova et al, 2001;Kraus et al, 2002;Tuglu et al, 2003;Basterzi et al, 2005;Himmerich et al, 2006;Leo et al, 2006;Sutcigil et al, 2007;Eller et al, 2008;Hernandez et al, 2008;Piletz et al, 2009;Song et al, 2009;Yoshimura et al, 2009;Chen et al, 2010;Jazayeri et al, 2010;Fornaro et al, 2011). Details about these studies are presented in Table 1.…”

Section: Selection Of Studiesmentioning

confidence: 99%

The Effect of Antidepressant Medication Treatment on Serum Levels of Inflammatory Cytokines: A Meta-Analysis

Hannestad

DellaGioia

Bloch

2011

Neuropsychopharmacol

807

517

View full text Add to dashboard Cite

Serum levels of inflammatory cytokines, for example, tumor necrosis factor alpha (TNFa), interleukin-6 (IL-6), and IL-1 beta , are elevated in subjects with major depressive disorder (MDD). The reason why this occurs is unclear. Elevated levels of inflammatory cytokines could be a result of brain dysfunction in MDD. It is also possible that inflammatory cytokines contribute to depressive symptoms in MDD. If the first assumption is correct, one would expect levels to normalize with resolution of the depressive episode after treatment. Several studies have measured changes in cytokine levels during antidepressant treatment; however, the results vary. The purpose of this study was to pool all available data on changes in serum levels of TNFa, IL-6, and IL-1b during antidepressant treatment to determine whether these levels change. Studies were included if they used an approved pharmacological treatment for depression, patients had a diagnosis of MDD, and serum levels of TNFa, IL-6, and/or IL-1b were measured before and after treatment. Twenty-two studies fulfilled these criteria. Meta-analysis of these studies showed that, overall, while pharmacological antidepressant treatment reduced depressive symptoms, it did not reduce serum levels of TNFa. On the other hand, antidepressant treatment did reduce levels of IL-1b and possibly those of IL-6. Stratified subgroup analysis by class of antidepressant indicated that serotonin reuptake inhibitors may reduce levels of IL-6 and TNFa. Other antidepressants, while efficacious for depressive symptoms, did not appear to reduce cytokine levels. These results argue against the notion that resolution of a depressive episode is associated with normalization of levels of circulating inflammatory cytokines; however, the results are consistent with the possibility that inflammatory cytokines contribute to depressive symptoms and that antidepressants block the effects of inflammatory cytokines on the brain.

show abstract

Variations in circulating cytokine levels during 52 week course of treatment with SSRI for major depressive disorder

Cited by 125 publications

References 48 publications

Prevalence of cardiovascular risk factors and concentration of C-reactive protein in Type D personality persons without cardiovascular disease

Prevalence of cardiovascular risk factors and concentration of C-reactive protein in Type D personality persons without cardiovascular disease

How to: Measuring blood cytokines in biological psychiatry using commercially available multiplex immunoassays

The Effect of Antidepressant Medication Treatment on Serum Levels of Inflammatory Cytokines: A Meta-Analysis

Contact Info

Product

Resources

About